COHERUS ONCOLOGY INC (CHRS) Stock News
NASDAQ:CHRS - Nasdaq - US19249H1032 - Common Stock - Currency: USD
CHRS Latest News, Press Relases and Analysis
Enbridge Is One of the Largest Energy Companies by Market Cap. But Is It a Buy?
Enbridge still has incredible competitive advantages. According to new research from The Motley Fool, Enbridge (NYSE: ENB), one of the biggest pipeline operators in the world, is now also one of the largest publicly traded energy companies. For years, investors have relied on the company for its juicy dividend, which now delivers a yield of nearly 6%.
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory
We came across a bullish thesis on Alpha Cognition Inc. Common Stock (ACOG) by anygal on r/investing on Reddit. In this article, we will summarize the bulls’ thesis on ACOG. Alpha Cognition Inc. Common Stock (ACOG)’s share was trading at $9.33 as of 30th May. ACOG’s forward P/E was 26.88 according to Yahoo Finance. Alpha Cognition Inc. […]
argenx SE (ARGX): A Bull Case Theory
We came across a bullish thesis on argenx SE (ARGX) by Simvestor08 on r/valueinvesting on Reddit.. In this article, we will summarize the bulls’ thesis on ARGX. argenx SE (ARGX)’s share was trading at $573.26 as of 30th May. ARGX’s trailing and forward P/E were 34.93 and 59.88 respectively according to Yahoo Finance. Argenx (ARGX), a $35 […]
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Steve Wagner’s Substack. In this article, we will summarize the bulls’ thesis on CHRS. Coherus BioSciences, Inc. (CHRS)’s share was trading at $0.77 as of 30th May. CHRS’s trailing P/E was 1.77 according to Yahoo Finance. Coherus BioSciences (CHRS), long overlooked by Wall Street, is […]
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology...
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
– First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor –...
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
– First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor –
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -12.90% and 85.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: BRTX
AppLovin (APP): AI-Powered Axon Platform Fuels Earnings and E-Commerce Growth
We recently published a list of 10 AI Stocks Making Moves This Week. In this article, we are going to take a look at where AppLovin Corporation (NASDAQ:APP) stands against other AI stocks making moves this week. Is China finally gaining supremacy in the AI arms race? Not quite, but executives from some of the […]
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in...
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025...
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
Coherus to Participate in Upcoming Investor Conferences
Coherus to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that the company will be...
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily...
Coherus divests Udenyca franchise to Intas for up to $558.4m
Intas’ US speciality division Accord BioPharma has taken responsibility for the franchise in the US.
Mentions: JPM
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
– $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts – – Coherus...
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif., April 01,...
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology...
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% year-over-year ––...
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and...
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will...
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including...